Medicare has locked in lower prices for Wegovy and 14 other high-cost medicines starting January 1, 2027, after federal officials completed a second cycle of drug negotiations. The Centers for Medicare & Medicaid Services says the new Maximum Fair Prices, or MFPs, will apply to treatments for cancer and chronic disease that are widely used by older adults. For seniors who rely on these drugs, the change sets a clear date when Medicare will start paying less and plans will have to adjust.
Why Medicares 2027 deal lowers the price of matters now
The stakes are immediate because CMS has already reached negotiated MFPs for 15 drugs in the second negotiation cycle, according to a primary CMS announcement. That means the price terms that will shape Medicare Part D spending in 2027 are no longer theoretical; they are set in federal agreements that manufacturers have accepted.
Those negotiated prices take effect on January 1, 2027, under the same CMS announcement, so insurers, pharmacy benefit managers and seniors now have a firm policy date to plan around. For people using Wegovy, the fact that its National Drug Codes are subject to the 2027 MFP, as documented on CMS’s negotiated price list, signals that this high-profile weight-loss and diabetes-related drug will be part of that shift.
The working hypothesis that these MFPs will cut Medicare Part D spending on the 15 drugs by at least 30 percent within two years cannot yet be confirmed or rejected. CMS has not released any percentage savings projections for this specific group of drugs, and the Government Accountability Office notes in report GAO-25-106996 that it is summarizing implementation of the Inflation Reduction Act’s drug pricing provisions rather than publishing forward-looking savings estimates. Any test of that 30 percent figure will have to wait for Medicare expenditure and claims files after 2027.
The evidence behind Medicares 2027 deal lowers the price of
The clearest evidence that Medicare will pay less for Wegovy and related products comes from CMS’s own negotiation program files. The agency maintains a machine-readable dataset that maps each selected drug to its National Drug Codes and lists the negotiated MFPs and per-unit or per-package prices, according to the Selected Drugs and Negotiated Prices page. Within that file, Wegovy NDCs are explicitly identified as subject to the 2027 MFP.
On the participation side, CMS states that manufacturers signed agreements for all 15 drugs in the IPAY 2027 group. A separate fact sheet confirms that Novo Nordisk signed a participation agreement covering Ozempic, Rybelsus and Wegovy, according to the agency’s manufacturer participation notice. That document also lays out the process timeline: CMS issues an initial offer by June 1, 2025, and the negotiation period ends November 1, 2025.
Those dates matter because they show that, even though MFPs take effect in 2027, the bargaining that determines those prices is concentrated in 2025. The same fact sheet identifies the drugs as IPAY 2027 products, tying them to the program year that begins when the MFPs become effective.
Oversight bodies have started to track how this structure works. The GAO report titled “Inflation Reduction Act of 2022 – Initial Implementation of Medicare Drug Pricing Provisions” explains that CMS is implementing a negotiation program with enforcement tools such as an excise tax for non-participation, according to GAO-25-106996. The same report notes that the first cycle of negotiated prices will take effect in 2026, which places the Wegovy group in the second wave.
Legal durability is another part of the evidence base. A nonpartisan analysis from the Congressional Research Service, cataloged as report R47682, describes major court challenges to the Medicare drug negotiation program and summarizes key arguments and outcomes, according to CRS material. That record shows that while litigation is active, the statutory framework that supports the 2026 and 2027 negotiated prices remains in force in the sources reviewed.
What remains unresolved for Medicares 2027 deal lowers the price of
Several important pieces are still missing from the public record. Exact per-unit MFP amounts for each Wegovy NDC and the other 14 drugs are stored inside the CMS ZIP data file, but those figures are not broken out in the high-level press materials. Without those numbers, independent analysts cannot yet calculate how far each negotiated price sits below current Part D net spending.
There is also no primary CMS or GAO data that quantifies projected beneficiary savings or utilization changes for the 15 drugs after 2027. GAO-25-106996 focuses on statutory design and early implementation steps, and it notes that an excise tax applies if a manufacturer does not participate, but it does not attach dollar estimates to the Wegovy cycle. That leaves the 30 percent spending reduction hypothesis as an open research question that will require Medicare claims data once the MFPs have been in effect.
On the industry side, the available federal sources do not include statements from Novo Nordisk or other manufacturers about how they might adjust production, research budgets or formulary strategies in response to the negotiated prices. The CMS participation fact sheet simply records that manufacturers signed the required agreements, without characterizing their future plans.
Beneficiary-facing portals such as Medicare.gov and Medicaid.gov provide general information on coverage and assistance but, in the cited materials, do not tie specific enrollment or cost-sharing guidance to the 2027 MFPs. That means seniors cannot yet look up how their out-of-pocket costs for Wegovy or the other 14 drugs will change on day one of 2027.
For now, the practical next step for patients and families is to watch how Part D plans update their formularies and cost-sharing tools as 2027 approaches, and to use official resources such as Medicare’s plan finder once those updates reflect the negotiated MFPs. The hard numbers that will confirm how much Medicare and its enrollees actually save from the Wegovy deal will only emerge after the program’s second cycle prices have been in place long enough to show up in spending data.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
